8th ASM Biodefense & Emerging Diseases Conference
For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.
Hôpital Robert Debré collaboration
On February 7th, 2010, Robert Debré Hospital (Paris-France) and Pherecydes Pharma signed an agreement to select bacteriophage variants for eradicating different Escherichia coli strains.
Presentation
Pherecydes Pharma is a SA (Société anonyme à directoire et conseil de surveillance) incorporated in December 2006. The company strategy is investing in innovation, to build added value through patents and technology platforms. Today our advances hold promises in several business areas from drug discovery to nanotechnologies. At this stage of development Pherecydes Pharma is open to develop industrial applications in the most promising ones, to focus on one or two key industrial sectors.
A state of the art facility within Biocitech Technology Park
Click on image to enlarge
A state of the art facility within Biocitech Technology Park
- An ideal situation within a secured park dedicated to biotechnology and other high technology fields
- Pherecydes Pharma holds the right to operate with harmful bacteria and genetically modified organisms
- Phercydes Pharma manages 115 m² of laboratories at Biocitech, including an isolated new L2 area, dedicated to infectious bacteria
Click on image to enlarge